TOXICITY OF WEEKLY LIPOSOMAL DOXORUBICIN AND PACLITAXEL IN METASTATIC BREAST CANCER (MBC)

被引:0
|
作者
Longo, F. [1 ]
Pellegrini, P. [1 ]
Ceccarelli, F. [1 ]
Borgomastro, A. [1 ]
Comito, T. [1 ]
Basile, M. L. [1 ]
De Biasio, G. [2 ]
Girolami, M. [2 ]
Spalletta, B. [1 ]
Di Seri, M. [1 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy
[2] Univ Roma La Sapienza, Dept Surg 4, Rome, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:23 / 23
页数:1
相关论文
共 50 条
  • [31] Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer
    Stavridi, Flora
    Palmieri, Carlo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1859 - 1869
  • [32] Weekly paclitaxel (T) and cisplatin (P) in patients (Pts) with metastatic breast cancer (Mbc) previously treated with antraciclines (A).
    Martinez, LC
    Campelo, RG
    Curbera, GA
    Ayerbes, MV
    Novoa, SA
    Hernández, PA
    Aparicio, LA
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 38 - 38
  • [33] Lack of cardiotoxicity in metastatic breast cancer (MBC) patients (pts) receiving doxorubicin/paclitaxel (DOX/PAC) combination
    Osmanova, L
    Stecenko, A
    Stenina, M
    Kassil, V
    Garin, A
    Tjulandin, S
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S325 - S325
  • [34] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [35] Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
    Bourgeois, Hugues
    Ferru, Aurelie
    Lortholary, Alain
    Delozier, Thierry
    Boisdron-Celle, Michelle
    Abadie-Lacourtoisie, Sophie
    Joly, Florence
    Chieze, Stephanie
    Chabrun, Virginie
    Gamelin, Erick
    Tourani, Jean-Marc
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (03): : 267 - 275
  • [36] Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer
    Hortobagyi, GN
    Holmes, FA
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (01) : S4 - S7
  • [37] Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer
    Hortobagyi, GN
    Holmes, FA
    Theriault, RL
    Rahman, Z
    Buzdar, AU
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (04) : 13 - 19
  • [38] Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients
    Susnjar, Snezana
    Bosnjak, Snezana M.
    Radulovic, Sinisa
    [J]. SUPPORTIVE CARE IN CANCER, 2008, 16 (12) : 1415 - 1418
  • [39] Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients
    Snezana Susnjar
    Snezana M. Bosnjak
    Sinisa Radulovic
    [J]. Supportive Care in Cancer, 2008, 16 : 1415 - 1418
  • [40] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study.
    Fabi, A
    Papaldo, P
    Ciccarese, M
    Salesi, N
    Lorusso, V
    Ferretti, G
    Carlini, P
    Sacchi, I
    Cecere, F
    Cognetti, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 80S - 80S